These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 28961308)

  • 21. FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma.
    Cohen MH; Johnson JR; Justice R; Pazdur R
    Oncologist; 2008 Jun; 13(6):709-14. PubMed ID: 18586926
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia/lymphoma: challenges, opportunities, and future directions.
    Miller LH; Maxa KL; Winter SS; Gossai NP
    Expert Rev Anticancer Ther; 2023; 23(12):1229-1236. PubMed ID: 37850259
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nelarabine for the treatment of patients with relapsed or refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma.
    DeAngelo DJ
    Hematol Oncol Clin North Am; 2009 Oct; 23(5):1121-35, vii-viii. PubMed ID: 19825456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MR imaging in nelarabine-induced myelopathy.
    Dua SG; Jhaveri MD
    J Clin Neurosci; 2016 Jul; 29():205-6. PubMed ID: 26899359
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nelarabine, cyclosphosphamide and etoposide for adults with relapsed T-cell acute lymphoblastic leukaemia and lymphoma.
    Luskin MR; Ganetsky A; Landsburg DJ; Loren AW; Porter DL; Nasta SD; Svoboda J; Luger SM; Frey NV
    Br J Haematol; 2016 Jul; 174(2):332-4. PubMed ID: 26403537
    [No Abstract]   [Full Text] [Related]  

  • 26. Nelarabine for T cell acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation: an opportunity to improve survival.
    Forcade E; Leguay T; Vey N; Baruchel A; Delaunay J; Robin M; Socié G; Dombret H; Peffault de Latour R; Raffoux E
    Biol Blood Marrow Transplant; 2013 Jul; 19(7):1124-6. PubMed ID: 23648236
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase I study of nelarabine in patients with relapsed or refractory T-ALL/T-LBL.
    Horibe K; Takimoto T; Yokozawa T; Makimoto A; Kobayashi Y; Ogawa C; Ohno R; Koh N; Katsura K; Tobinai K
    Rinsho Ketsueki; 2011 Jun; 52(6):406-15. PubMed ID: 21737993
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of nelarabine in patients with relapsed or refractory T-cell acute lymphoblastic leukemia: a systematic review and meta-analysis.
    Kathpalia M; Mishra P; Bajpai R; Bhurani D; Agarwal N
    Ann Hematol; 2022 Aug; 101(8):1655-1666. PubMed ID: 35727338
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation.
    Gökbuget N; Basara N; Baurmann H; Beck J; Brüggemann M; Diedrich H; Güldenzoph B; Hartung G; Horst HA; Hüttmann A; Kobbe G; Naumann R; Ratei R; Reichle A; Serve H; Stelljes M; Viardot A; Wattad M; Hoelzer D
    Blood; 2011 Sep; 118(13):3504-11. PubMed ID: 21715318
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Complete paraplegia after nelarabine treatment in a T-cell acute lymphoblastic leukemia adult patient.
    Papayannidis C; Iacobucci I; Abbenante MC; Curti A; Paolini S; Parisi S; Baccarani M; Martinelli G
    Am J Hematol; 2010 Aug; 85(8):608. PubMed ID: 20658590
    [No Abstract]   [Full Text] [Related]  

  • 31. Nelarabine-induced myelopathy in patients undergoing allogeneic hematopoietic cell transplantation: a report of three cases.
    Fukuta T; Tanaka T; Hashimoto T; Isahaya K; Kubo Y; Yamano Y; Satomi K; Hiraoka N; Shirakawa N; Arakawa A; Ogawa C; Nishimura N; Aoki J; Ito A; Inamoto Y; Kim SW; Fukuda T
    Int J Hematol; 2023 Jun; 117(6):933-940. PubMed ID: 36705847
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Coma associated with nelarabine in an elderly patient with T-cell acute lymphoblastic leukemia and severe chronic renal disease.
    Nishijima TF; Shea TC; Wood WA; Voorhees PM; Jamieson K
    Leuk Lymphoma; 2016; 57(4):957-60. PubMed ID: 26293208
    [No Abstract]   [Full Text] [Related]  

  • 33. Clofarabine and nelarabine: two new purine nucleoside analogs.
    Gandhi V; Plunkett W
    Curr Opin Oncol; 2006 Nov; 18(6):584-90. PubMed ID: 16988579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma.
    Kadia TM; Gandhi V
    Expert Rev Hematol; 2017 Jan; 10(1):1-8. PubMed ID: 27869523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Severe liver injury following nelarabine chemotherapy for T-cell lymphoblastic lymphoma].
    Iino M
    Rinsho Ketsueki; 2009 Jan; 50(1):49-51. PubMed ID: 19225230
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Irreversible neurological defects in the lower extremities after haploidentical stem cell transplantation: possible association with nelarabine.
    Kawakami M; Taniguchi K; Yoshihara S; Ishii S; Kaida K; Ikegame K; Okada M; Watanabe S; Nishina T; Hamada H; Nakagawa M; Ogawa H
    Am J Hematol; 2013 Oct; 88(10):853-7. PubMed ID: 23757212
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nelarabine toxicity in children and adolescents with relapsed/refractory T-ALL/T-LBL: can we avoid throwing the baby out with the bathwater?
    Malone A; Smith OP
    Br J Haematol; 2017 Oct; 179(2):179-181. PubMed ID: 28891074
    [No Abstract]   [Full Text] [Related]  

  • 38. Nelarabine: new drug. T-lymphoblastic leukaemia/lymphoma: more evaluation needed.
    Prescrire Int; 2009 Feb; 18(99):3-5. PubMed ID: 19382393
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nelarabine: efficacy in the treatment of clinical malignancies.
    Roecker AM; Allison JC; Kisor DF
    Future Oncol; 2006 Aug; 2(4):441-8. PubMed ID: 16922610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nelarabine: when and how to use in the treatment of T-cell acute lymphoblastic leukemia.
    Shimony S; DeAngelo DJ; Luskin MR
    Blood Adv; 2024 Jan; 8(1):23-36. PubMed ID: 37389830
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.